Table 6.
General features of patients with adjunctive ALT with and without removal of the CVC.
| General Features | CVC Not Removed (n = 28) | CVC Removed (n = 13) | p Value |
|---|---|---|---|
| Age, months, median (IQR) | 40 (23.4–215.8) | 31.8 (21.8–58.4) | 0.272 |
| Male, n (%) | 22 (78.6%) | 4 (30.7%) | 0.698 |
| Underlying condition, n (%) | 0.305 | ||
| Hematologic tumor | |||
| leukemia | 12 | 9 | |
| lymphoma | 2 | 0 | |
| Solid tumor | 10 | 3 | |
| Other hematologic conditions | |||
| sickle cell disease | 1 | 0 | |
| beta-thalassemia major | 3 | 0 | |
| Langerhans histiocytosis | 0 | 1 | |
| No BMT/ with BMT, n (%) | 19 (86.4)/3 (13.6) | 13 (100)/0 (0) | 0.279 |
| WBC cells/mm3 median (IQR) | 2650 (573–5625) | 3000 (600–10,700) | 0.612 |
| Severe neutropenia, n (%) | 0.493 | ||
| no | 18 (64.3) | 10 (43.5) | |
| yes | 10 (35.7) | 3 (56.5) | |
| Total parenteral nutrition, n (%) | 1 (3.5) | 0 (0) | 1 |
| Type of catheter, n (%) | 0.539 | ||
| Port-a-Cath ® | 25 (89.3) | 13 (100) | |
| Hickman ® | 3 (10.7) | 0 | |
| Catheter insertion site, n (%) | 1 | ||
| subclavian | 7 (58.3) | 4 (66.7) | |
| jugular | 4 (33.4) | 2 (33.4) | |
| femoral | 0 | 0 | |
| superior cava vein | 1 (8.3) | 0 | |
| not recorded/missing data | 0 | 0 | |
| Type of ALT | 0.0336 | ||
| vancomycin | 20 (71.4) | 6 (45.1) | |
| amikacin | 4 (14.3) | 5 (38.5) | |
| ciprofloxacin | 2 (7.1) | 1 (8.2) | |
| cefazolin | 1 (3.6) | 0 | |
| gentamicin | 1 (3.6) | 1 (8.2) | |
| ESBL, n (%) | 0 | 1 (8.2) | 0.325 |
CVC: Central venous catheter. IQR: Interquartile range. BMT: Bone marrow transplantation. WBC: White blood cells. ALT: Antibiotic lock therapy. ESBL: Extended spectrum beta-lactamase.